Calendar

Week of Apr 27, 2026

Apr 29, 2026phase 1 initiation91d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

full page →adenovirus vector (spike protein) vaccine →source: globaldata

Apr 29, 2026phase 2 completion91d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

full page →(amoxicillin + clavulanic acid) →source: globaldata

Apr 29, 2026phase 2 initiation91d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

full page →norfloxacin →source: globaldata

Apr 29, 2026phase 2 initiation91d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

Therapy area: Infectious Disease. Indication: Hepatitis B

full page →HH-006 →source: globaldata

Apr 30, 2026constraining patent expiry europe90d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

full page →telavancin hydrochloride →source: globaldata

Apr 30, 2026patent expiry90d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

full page →isavuconazonium sulfate →source: globaldata

Apr 30, 2026phase 1 completion90d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →tegoprazan →source: globaldata

Apr 30, 2026phase 1 completion90d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

full page →MKK-900 →source: globaldata

Apr 30, 2026phase 1 completion90d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

full page →ciprofloxacin →source: globaldata

Apr 30, 2026phase 1 initiation90d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

full page →GS-1701 →source: globaldata

Apr 30, 2026phase 1 initiation90d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →DASATINIB →source: globaldata

Apr 30, 2026phase 1 2 completion90d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 2 completion90d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion90d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion90d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion90d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

Week of Apr 27, 2026